Latest news

• Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

  Valent claimed a US approval for this drug last year. Gedeon Richter got the nod for Reagila (cariprazine) as a treatment for schizophrenia - which follows US approval in 2015 - and Chiesi

• Rare disease therapies head the ‘class of 2015’

  EU. cariprazine. Vraylar. schizophrenia / bipolar disorder. dopamine D3/D2 receptor partial agonist.

• Allergan and Gedeon finally get antipsychotic green light

  Vraylar (cariprazine) is a dopamine D2, D3 receptor partial agonist and was turned down by the FDA in 2013, with the agency requesting more data including another clinical trial despite acknowledging ... Analysts at Canaccord Genuity have indicated they

• More waiting for Allergan and Gedeon Richter's antipsychotic

  FDA announced it will take another three months to review cariprazine for schizophrenia. ... end of 2013, despite concluding that cariprazine showed efficacy in the two indications. .

• J&J gets quicker review for schizophrenia depot in US

  in the summer, as well as two novel antipsychotics - Otsuka/Lundbeck's brexpiprazole and cariprazine from Actavis and Gedeon Richter. ... Cariprazine was turned down by the FDA towards the end of 2013 but has just shown activity in a new phase III trial,